Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novimmune gets CHF58mm in Series B round; later adds tranches, bringing total to CHF200.5mm

Executive Summary

Novimmune (monoclonal antibodies for immune-related conditions and inflammation) raised CHF58mm ($46mm) through its Series B private placement that was led by new investor BZ Bank. Another new buyer, Pictet Private Equity Investors, was joined by existing backers Lombard Odier Darier Hentsch, Novartis Venture Fund, and Aravis Venture.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies